In 2010, Merck received no warning letters or untitled letters from the U.S. FDA Division of Drug Marketing, Advertising and Communication (DDMAC) or from the Advertising and Promotional Labeling Branch (APLB) of the FDA Center for Biologics Evaluation and Research.

Following the implementation of the revised Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, Merck completed self-certification in 2009 and 2010.